News
CERT
10.53
-1.68%
-0.18
Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
Simply Wall St · 3h ago
Analysts Forecast 16% Gains Ahead For IYH
NASDAQ · 2d ago
Weekly Report: what happened at CERT last week (1104-1108)?
Weekly Report · 4d ago
CERTARA INC <CERT.O>: JEFFERIES CUTS TARGET PRICE TO $12.50 FROM $15.50
Reuters · 4d ago
Certara’s Balanced Outlook: Hold Rating Amid Strategic Review and Biosimulation Growth
TipRanks · 11/08 07:35
Certara Hold Rating Maintained Amid Mixed Performance and Regulatory Concerns
TipRanks · 11/08 07:29
Forecasting The Future: 4 Analyst Projections For Certara
Benzinga · 11/07 17:00
Certara Is Maintained at Equal-Weight by Barclays
Dow Jones · 11/07 14:59
Certara Price Target Cut to $12.00/Share From $14.00 by Barclays
Dow Jones · 11/07 14:59
Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $12
Benzinga · 11/07 14:48
Certara price target lowered to $12 from $14 at Barclays
TipRanks · 11/07 10:45
Barclays Keeps Their Hold Rating on Certara (CERT)
TipRanks · 11/07 08:17
JMP Securities Sticks to Their Hold Rating for Certara (CERT)
TipRanks · 11/07 05:37
CERTARA INC <CERT.O> FY2024 REV VIEW $386.5 MLN -- LSEG IBES DATA
Reuters · 11/06 21:15
CERTARA Q3 ADJUSTED EPS USD 0.13 VS. IBES ESTIMATE USD 0.11
Reuters · 11/06 21:15
Certara Price Target Cut to $13.00/Share From $18.00 by Baird
Dow Jones · 11/05 12:22
Certara Is Maintained at Neutral by Baird
Dow Jones · 11/05 12:22
Baird Maintains Neutral on Certara, Lowers Price Target to $13
Benzinga · 11/05 12:12
Certara price target lowered to $13 from $18 at Baird
TipRanks · 11/05 11:55
Weekly Report: what happened at CERT last week (1028-1101)?
Weekly Report · 11/04 09:22
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.